Riskpilot← Back to searchSign inGet full accessInitiator Pharma A/S
A/SActiveCVR 37663808Ole Maaløes Vej 3Research and experimental development on natural sciences and engineering · NACE 7210Est. 20162 employees
Revenue 2024
DKK -11,1M
-53% vs 2023
EBITDA margin
131.0%
+46% vs 2023
Equity ratio
93.4%
Financial strength
Net profit 2024
DKK -12,9M
+43% vs 2023
| Revenue | DKK -11,1M | -53% |
| EBITDA | DKK -14,5M | +46% |
| Net profit | DKK -12,9M | +43% |
| Total assets | DKK 15,8M | -47% |
| Equity | DKK 14,8M | +32% |
| Employees | 2 | — |
Legal name
Initiator Pharma A/S
CVR number
37663808
Legal form
Aktieselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
2. maj 2016
Share capital
DKK 7.187.554
Employees
2 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør i forening med et bestyrelsesmedlem eller af to bestyrelsesmedlemmer i forening eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at forske, udvikle, producere og sælge lægemidler og lægemiddelkandidater, relaterede teknologier, service og andre beslægtede forretningsområder efter bestyrelsens skøn.
Address
Ole Maaløes Vej 3
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | -9.299 | -22 | -38.425 | -23.413 | -11.073 |
| Staff expenses | -1.206 | -1 | -3.315 | -3.617 | -3.427 |
| EBITDA | -10.505 | -23 | -41.740 | -27.030 | -14.502 |
| Depreciation & amort. | -26 | -0 | -0 | -0 | -0 |
| EBIT | -10.531 | -23 | -41.740 | -27.030 | -14.502 |
| Net financials | -291 | -1 | -2.392 | -677 | -333 |
| Profit before tax | -10.240 | -24 | -44.132 | -27.707 | -14.836 |
| Tax | -1.543 | -3 | -5.677 | -4.834 | -1.904 |
| Net profit | -8.697 | -21 | -38.455 | -22.873 | -12.932 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 15.603 | 54 | 48.345 | 29.786 | 15.835 |
| Equity | 14.409 | 35 | 34.023 | 11.162 | 14.782 |
| Long-term debt | 0 | 13 | 12.577 | 15.437 | 0 |
| Short-term debt | 1.194 | 5 | 1.745 | 3.187 | 1.053 |
| Total debt | 1.194 | 5 | 14.322 | 18.624 | 1.053 |
EBITDA margin
-1450200000.0%
This company
15.8%
Market median
-9178481113% vs market
20202024
Equity ratio
93.4%
This company
38.2%
Market median
+145% vs market
20202024
Return on equity
-87.5%
This company
18.4%
Market median
-576% vs market
20202024
Net profit margin
-1293200000.0%
This company
8.1%
Market median
-15965432199% vs market
20202024
Asset turnover
-0.70×
This company
1.12×
Market median
-163% vs market
20202024
Debt / equity
0.07×
This company
0.62×
Market median
+89% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
DA Founder | Founder | 2016 |
CE Management | Management | 2016 |
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Board of Directors | 2021 | |
| Board of Directors | 2025 | |
| Chairman | 2016 | |
| Board of Directors | 2016 | |
| Board of Directors | 2022 | |
| Former (3) | ||
| Board of Directors | 2016 – 2025 | |
| Board of Directors | 2016 – 2016 | |
| Board of Directors | 2016 – 2016 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 10–14.99% | 10–14.99% | 2021 | |
| Individual | 5–9.99% | 5–9.99% | 2021 | |
| Individual | 5–9.99% | 0% | 2017 | |
| Company | 5–9.99% | 5–9.99% | 2017 | |
| Individual | 50–66.65% | 50–66.65% | 2016 | |
| Individual | 5–9.99% | 5–9.99% | 2017 | |
| Individual | 5–9.99% | 0% | 2017 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Initiator Pharma A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| DanPET AB | Founder | 0 companies |
| Claus Elsborg Olesen | Management | 0 companies |
| Annette Ingegerd Marie Colin | Board of Directors | 0 companies |
| Henrik Kristian Moltke | Board of Directors | 0 companies |
| Göran Albert Torstensson Ando | Board of Directors | 0 companies |
| Ulf Simonsen | Board of Directors | 0 companies |
| Gunnar Magnus Severus Modée Persson | Chairman | 0 companies |
| Peter Joakim Holm | Board of Directors | 0 companies |
| Dan Leif Peters | Board of Directors | 0 companies |
| Ylva Gunilla Ekström | Board of Directors | 0 companies |